Company / R&D per Share
CNBX Pharmaceuticals Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
-
FY2025
5-year range
$0.00 / $0.35
FY2021-FY2025
Trend
-100.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $0.35 to $0.00 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share decreased 100.0% year-over-year.
- Peak r&d per share was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1304.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.00 | -100.0% |
| FY2024 | $0.01 | -97.5% |
| FY2023 | $0.35 | +2556.7% |
| FY2021 | $0.01 | +4.8% |
| FY2020 | $0.01 | -1.5% |
| FY2019 | $0.01 | +514.7% |
| FY2017 | $0.00 | +18.1% |
| FY2016 | $0.00 | - |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026